Grindeks has decided to leave the Latvian Employers’ Confederation (LEC), strongly arguing that the management of LEC and specifically its president Vitalijs Gavrilovs essentially breach...
JSC Grindeks informs that it has successfully finished the clinical trial on the influence of the brand product Mildronate® on the treatment of angina. International...
JSC Grindeks informs, that starting from December 10, 2009 Rimantadine-Grindeks 50mg N20 tablets, the antiviral medication effective against seasonal influenza, are available in chemistry shops...
Joint Stock Company Grindeks informs on launching of Rimantadine-Grindeks 50mg – the effective and recognized antiviral medication for treatment of seasonal flu. After the receiving...
From October 13 to 15, JSC Grindeks will participate in the international exhibition „CPhI Worldwide 2009″ in Feria de Madrid, Spain. During exhibition Grindeks will...
JSC Grindeks objects to the broadcasted information by “Nekā Personīga” on TV3, on September 20, 2009, that the price of the Mildronate in Latvia is...
By increasing production capacities of the company, taking care of environment protection with high responsibility and investing LVL 2.5 million, on the eve of the...
Grindeks was proposed by the pharmaceutical company “Instituto Biológico Argentino S.A.I.C.” (“BIOL”) for a joint international project “Oxytocin in Unijecttm” conducted by PATH*. Within the...
